GlassScriptPhysician profile
John Gerard Spethman
NPI 1942239355
$1,186.15
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $140.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $194.59 | 2019 | |
| Astellas Pharma US INC | $180.57 | 2019 | |
| Glaxosmithkline, LLC. | $143.63 | 2019-2020 | |
| Lilly USA, LLC | $125.95 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $78.46 | 2019 | |
| Sanofi-Aventis U.S. LLC | $72.02 | 2019-2020 | |
| Amgen INC. | $64.83 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $58.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.58 | 2019 | |
| Allergan, INC. | $35.85 | 2020 | |
| Pfizer INC. | $25.56 | 2019 | |
| Shire North American Group INC | $24.17 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.34 | 2019 | |
| Genentech USA, INC. | $15.12 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wright Medical Technology, INC. | $13.43 | 2019 | |
| Kyowa Kirin, INC. | $13.28 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.51 | 2019 | |
| Amarin Pharma, INC. | $11.16 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Spethman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.